Japanese Pharma Giant Takeda Commits IDR 539 Billion to Indonesia's Plasma Ecosystem
The Ministry of Investment and Downstream Industry/Investment Coordinating Board (BKPM) has welcomed the investment commitment of Japanese biopharmaceutical company Takeda to develop the plasma-derived medicinal products (PODP) ecosystem in Indonesia.
In the initial phase, Takeda will invest up to US$30 million, or around Rp539 billion, over two years to build a plasma bank network as the foundation for developing the national plasma industry.
Minister of Investment and Downstream Industry/BKPM Head Rosan P Roeslani said Takeda’s investment reflects the growing confidence of global investors in Indonesia’s investment prospects, particularly in the high-tech health industry sector.
“This is a strategic investment that not only brings additional capital but also opens opportunities for technology transfer, human resource development, and the creation of highly skilled jobs. The government continues to encourage investments that add value and strengthen national industrial capacity so that Indonesia can become a hub for health manufacturing and innovation in the region,” Rosan said in a statement quoted on Tuesday (14/7/2026).
The partnership also aligns with the economic transformation agenda through downstreaming in various strategic sectors, including health, to enhance the competitiveness of national industry and strengthen Indonesia’s position in global supply chains.
Japan itself is one of Indonesia’s strategic investment partners. According to data from the Ministry of Investment and Downstream Industry/BKPM, in the first quarter of 2026 Japan ranked fifth among Indonesia’s principal investors, reaching US$1 billion.
Meanwhile, Japan’s total realised investment between 2021 and Q1 2026 reached US$18.1 billion, with average growth of 13.2% and employment absorption of 299,460 people. This provides a strong foundation for developing investment cooperation in various priority sectors, including health.
Through this collaboration, the Government hopes Indonesia will not only improve public access to much-needed plasma-derived medicinal products but also build a competitive, innovative and sustainable biopharmaceutical industry ecosystem.
The first plasma bank is targeted to begin operating in 2027 as part of developing a national plasma network that meets international standards.
Source: jawawa.id (https://jawawa.id/newsitem/japanese-pharma-giant-takeda-commits-idr-539-billion-to-indonesias-plasma-ecosystem-1784008248)
Originally published by wartaekonomi.co.id (https://wartaekonomi.co.id/read622376/investasi-rp539-miliar-raksasa-farmasi-jepang-takeda-masuk-ekosistem-plasma-indonesia), translated from Indonesian